<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: OrbiMed Israel GP Ltd. -->
          <cik>0001569590</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001720580</issuerCik>
      <issuerName>Adicet Bio, Inc.</issuerName>
      <secFileNumber>001-38359</secFileNumber>
      <issuerAddress>
        <com:street1>131 DARTMOUTH STREET</com:street1>
        <com:street2>3RD FLOOR</com:street2>
        <com:city>BOSTON</com:city>
        <com:stateOrCountry>MA</com:stateOrCountry>
        <com:zipCode>02116</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>617-482-2333</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>OrbiMed Israel Partners Limited Partnership</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Shareholder</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>Themis Trading LLC</name>
        <address>
          <com:street1>10 Town Square</com:street1>
          <com:street2>Suite 100</com:street2>
          <com:city>Chatham</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>07928</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>64242</noOfUnitsSold>
      <aggregateMarketValue>413076.06</aggregateMarketValue>
      <noOfUnitsOutstanding>9596407</noOfUnitsOutstanding>
      <approxSaleDate>04/07/2026</approxSaleDate>
      <securitiesExchangeName>Nasdaq Stock Market</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <acquiredDate>09/15/2020</acquiredDate>
      <natureOfAcquisitionTransaction>Merger</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Issuer</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>64242</amountOfSecuritiesAcquired>
      <paymentDate>09/15/2020</paymentDate>
      <natureOfPayment>N/A</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks>OrbiMed Israel BioFund GP Limited Partnership is the general partner of OrbiMed Israel Partners Limited Partnership. OrbiMed Israel GP Ltd. is the general partner of OrbiMed Israel BioFund GP Limited Partnership.</remarks>
    <noticeSignature>
      <noticeDate>04/07/2026</noticeDate>
      <signature>/s/ Carl L. Gordon, Director, OrbiMed Israel GP Ltd., general partner of the general partner of OrbiMed Israel Partners Limited Partnership</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
